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VENOUS THROMBOSIS
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Casella IB, Presti C, Aun R, Benabou JE, Puech-Leão P. Late results of catheter-directed recombinant tissue plasminogen
activator fibrinolytic therapy of iliofemoral deep venous thrombosis. Clinics. 2007;62(1):31-40.
PURPOSE: To evaluate the efficacy of catheter-directed low-dose recombinant tissue-type plasminogen activator infusion in the
treatment of iliofemoral deep venous thrombosis and prevention of post-thrombotic syndrome.
METHOD: Eighteen patients (out of 260 evaluated) with acute iliofemoral deep venous thrombosis and no previous evidence of
venous insufficiency were prospectively selected for thrombolytic therapy. Catheter-directed low-dose recombinant tissue-type
plasminogen activator (1 mg/h) was infused into the thrombotic segments.
RESULTS: Effective fibrinolysis was achieved in 14 of 18 cases, with correlation between effective fibrinolysis and major/
complete resolution of acute signs and symptoms (P <.01). There were no episodes of major complications. Four patients presented
with early rethrombosis (1 to 8 weeks). Individuals were followed for a period up to 131 weeks (average, 85.2). The incidence of
clinical signs and symptoms of venous insufficiency and duplex-scan findings of valvular reflux was significantly lower in the
patients in which lytic therapy succeeded and patency was kept, compared with patients experiencing acute therapeutic failure or
rethrombosis (P <.01).
CONCLUSIONS: Low-dose recombinant tissue-type plasminogen activator fibrinolytic therapy is safe and effective in the treatment
of acute iliofemoral venous thrombosis. The late evolution as revealed clinically and by ultrasound was superior in patients for
whom lytic therapy was effective.
KEYWORDS: Deep venous thrombosis. Fibrinolysis. rt-PA. Post-thrombotic syndrome. Venous insufficiency.
INTRODUCTION
Deep venous thrombosis (DVT) of the lower limbs can
lead to functional and anatomic venous alterations that
characterize post-thrombotic syndrome. Although the de-
terminant factors that result in chronic venous insufficiency
after a DVT episode are not completely understood, there
appears to be a strong correlation between post-thrombotic
syndrome and the extent of the thrombotic process. The
progress of distal DVTs is usually benign,1,2 with a high
rate of recanalization and a low rate of venous reflux. On
the other hand, the persistence of chronic occlusions and
venous reflux is common in extensive DVTs.3,4 Up to 96%
of patients with proximal DVT may progress with reflux
and/or venous obstruction.5 It should also be noted that ve-
nous segments with evidence of reflux after DVT recanali-
zation were those presenting a spontaneous fibrinolysis up
to 7 times longer than the observed in competent segments,
suggesting that thrombus removal time is also an impor-
tant factor in vein valve preservation.6
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The use of locally infused fibrinolytic agents presents
the possibility of direct intervention for massive and im-
mediate thrombus removal.7-14 Theoretically, this specific
feature of thrombolysis should lead to immediate improve-
ment of clinical results in extensive cases of DVT, as well
as to preservation of valvular competence and venous wall
morphology as has been described by experimental stud-
ies.15,16
The purpose of this study was to evaluate the late re-
sults of low-dose of recombinant tissue-type plasminogen
activator (rt-PA) catheter-directed thrombolysis in proximal
DVT, studying the effectiveness of fibrinolysis in preven-
tion of late clinical and echographic sequelae characteris-
tic of post-thrombotic syndrome.
METHOD
In a prospective study between June 2001 and January
2005, 260 patients with clinical and duplex-scan diagno-
sis of acute lower limb DVT were evaluated. The inclu-
sion criterion for thrombolytic therapy was the presence of
acute unilateral iliofemoral DVT (up to 14 days) without
any history or diagnostic evidence of previous episodes of
DVT or venous insufficiency of the affected limb.
Patients with the described characteristics were ex-
cluded if any of the following features were present:
contraindications to the use of thrombolytic agents, such
as history of major bleeding; recent delivery or major sur-
gery (up to 10 days); neurosurgical intervention (up to 3
months); and recent significant trauma or disease with
known risk of hemorrhagic complications. Patients with
renal failure or previous history of allergic reaction to io-
dine contrast were also excluded. The age limit for throm-
bolysis was arbitrarily set at 70 years. Inclusion was con-
ditional to the signature of the informed consent agreement.
This clinical research project was approved by the Institu-
tional Committee of Ethics in Research. In adherence to
the above criteria, 18 of the examined subjects fulfilled the
selective criteria for thrombolysis therapy and were in-
cluded.
Access to the deep venous system was obtained through
surgical dissection of the retromalleolar ipsilateral lesser
saphenous vein (LSV) in 11 cases and of the proximal
lesser saphenous vein just below the genicular fold in 4
cases. The dissection site was defined by previous duplex
scan image. Dissection of distal posterior tibial vein was
performed in 1 patient in which the lesser saphenous vein
was considered inadequate. The technique of popliteal vein
puncture with ultrasound guidance became accessible dur-
ing this study and was performed in 2 patients.
After insertion of a 5F sheath, a multiple-side-hole 5F
catheter was positioned under radioscopic viewing in the
iliofemoral thrombotic segments, and it was eventually re-
positioned to a distal position during therapy. In the 2 later
cases, a coaxial infusion system consisting of a Katzen in-
fusion wire (Boston Scientifics, USA) inserted through the
catheter was used.
Initial prethrombolysis phlebographic images were
taken to assess the extent of the thrombotic process, using
30 mL of iodinated contrast infused through the sheath and/
or the catheter.
The patients were then sent to the semi-intensive care
unit, and infusion of the rt-PA (“Actilyse”, Boehringer
Ingelheim, Germany) was initiated at a constant dose of 1
mg/h diluted in 0.9% saline, without bolus. Dilution of the
drug varied from patient to patient, ranging from 0.025 to
0.1 mg/mL during the study. In case of coaxial infusion,
the lytic solution was divided for the two devices.
Unfractionated heparin was utilized as an adjuvant drug,
administered by systemic infusion at an initial dose of
12,000 IU/day, and then adjusted to maintain a partial
thromboplastin time of close to 60 seconds.
Patients were continuously monitored to detect clini-
cal sings and symptoms of complications such as pulmo-
nary embolism or hemorrhages. Blood samples were taken
every 12 hours for hematocrit, hemoglobin, partial throm-
boplastin time, fibrinogen, and platelet count to adjust the
heparin dose and detect blood loss.
Control phlebographies were performed every 12 to 15
hours. The initial and control phlebographies were submit-
ted to a quantitative thrombus volume estimation as de-
scribed by Marder et al17 and modified by the authors, em-
ploying some of the parameters proposed by the Commit-
tee for International Standards of Chronic Venous Diseases18
(Figure 1). The differences in the phlebography values were
used to estimate the percentage of thrombolysis, and a 50%
to 100% removal of the thrombus was considered to be
technically satisfactory.7
Venous segments assessed: Common iliac, external iliac, com-
mon femoral, proximal and distal superficial femoral* and pop-
liteal vein.
Phlebographic scoring of venous thrombosis: Complete occlusion
– 3; Segmental occlusion – 2; Non-occlusive parietal thrombo-
sis – 1; Absence of thrombi – 0.
Total score calculated by the sum of each segment score.
Final score calculated by percentual difference between pre
and post-thrombolysis phlebographies
*The presence of a second superficial femoral vein should be con-
sidered.
Figure 1 - Measurement of thrombotic volume of venous segments
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Postfibrinolysis procedure
Infusion of rt-PA was interrupted in case of significant
bleeding, fibrinogen levels below 100 mg/dL, or absence
of radiological improvement in 2 consecutive phlebograms.
At the end of the procedure, independently of thrombolytic
success, a therapeutic dose of continuous intravenous
unfractionated heparin treatment was initiated (20 IU/K/
h), followed by oral anticoagulation with warfarin. Adjuvant
elastic compression therapy was recommended and encour-
aged. After hospital discharge, the patients were followed
weekly in the outpatient clinic during the first month and
at monthly intervals thereafter. During follow-up, patients
underwent multiple duplex scan examinations of the deep
venous system of the affected lower limb. The scope of this
procedure was to confirm patency of the deep venous sys-
tem, presence of residual thrombi in the segments treated
and in the infragenicular veins, and the presence of venous
reflux. Generally, duplex-scan exams were performed at an
early stage (up to 3 months postdischarge), during an in-
termediate stage, and at the end of the outpatient follow-
up by the same qualified examiner using a HDI 5000 Du-
plex ultrasound system (Advanced Technology Laborato-
ries, Bothell, WA, USA). Valvular reflux was confirmed by
the echographic technique described by Masuda et al.19
Reflux was assessed only in patent venous segments, since
residual thrombi can provoke temporary reflux that can
eventually disappear after recanalization. The venous seg-
ments studied included common iliac, external iliac, com-
mon femoral, deep femoral, superficial femoral, popliteal,
anterior and posterior tibial veins, and the lesser saphen-
ous vein, the latter only when used as a vascular access.
At the end of the clinical follow-up, the subjects were
classified according to degree of clinical sequelae based on
volume of residual edema, signs of exacerbation of super-
ficial venous circulation, intensity of pain or discomfort,
and subjective perception of life quality preservation.
In the statistical analysis, the Spearman’s test was used
to compare 2 quantitative variables. The Mann-Whitney’s
“U” test compared the quantitative data between 2 groups.
Binary or dichotomized data were compared with 2 x 2 ta-
bles and submitted to the Fisher's exact test. P values of
less than 0.05 were considered significant.
RESULTS
The clinical onset of the DVT ranged from 2 to 14 days
(7.2 ± 4.2 days). The chief characteristics and immediate
results of this therapy are summarized in Table 1. The per-
centage of thrombus removal ranged from 11% to 100%
(mean/SD, 68.3% ± 25.2%). The percentage of thromboly-
sis in 14 subjects was greater than 50% of the
supragenicular thrombotic volume. Significant or complete
clinical improvement occurred in 12 of the 18 individuals.
A statistically significant correlation was found between the
percentage of thrombus removal and degree of clinical im-
provement (P < 0.01, Table 2).
The duration of the rt-PA infusion ranged from 12 to
74 hours (42.1 ± 16.8 hours), and the total dose used was
12 to 72 mg (39.7 ± 16.1 mg). No correlations were noted
between the dilution, dose or duration of the rt-PA infu-
Table 1 - Clinical characteristics and initial results of thrombolysis
Age,Gender Limb Onset of % of throm- Clinical Time/h Venous stenosis Complications
symptoms (days) bolysis Improvement Infusion or occlusion
1 54,M L 14 89 ++ 42
2 56,M L 7 83 +++ 15
3 17,F R 3 33 + 36
4 19,F R 4 39 + 56
5 63,F R 12 11 - 12
6 33,M L 3 93 ++ 32 CIV hematoma
7 20,F L 4 83 +++ 56
8 33,F L 4 100 ++ 60 CIV
9 42,F L 14 63 ++ 43 hematuria
10 24,F L 3 59 +++ 57
11 41,M L 9 81 ++ 29
12 30,F L 9 58 + 59
13 46,F R 10 56 ++ 33
14 21,F L 12 63 + 45
15 56,F L 12 71 ++ 42
16 18,F L 2 48 + 20  low fibrinogen
17 17,F R 5 100 +++ 74 IVC
18 58,F L 4 100 +++ 48 CIV
F = female; M = male; L = left; R = right; (-) = absent, (+) = poor, (++) = significant,  (+++) = complete; CIV = common iliac vein; IVC = inferior vena cava
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sion and the percentage of lysis or clinical improvement.
No correlation was established between clinical onset of
disease and acute clinical results (P = 0.59), total dose of
rt-PA (P = 0.69), or percentage of lysis (P = 0.98).
Complications, concomitant venous stenosis, and early
rethrombosis
Bleeding at the catheter insertion site occurred only in
cases of lesser saphenous vein dissection, 3 in the
retromalleolar region, and 1 in the knee fold. It was con-
trolled in all cases by simple elevation of the limb and ap-
plication of a compressive bandage, without requiring trans-
fusion or interruption of the procedure. Patient #09 dis-
played gross hematuria after 40 hours on rt-PA, with spon-
taneous remission after interruption of lysis. At the end of
the thrombolysis, patient #06 demonstrated an extensive
hematoma of the left upper limb related to accidental punc-
ture of the deep vein for collection of a blood sample.
Patient #16 presented with low serum fibrinogen levels
(< 80 mg/dL) during the first hours of rt-PA infusion, and
lysis was interrupted in spite of the absence of clinical or
laboratorial sign of blood loss.
After complete lysis of acute thrombi, patient #17 was
diagnosed with chronic caval obstruction with partial re-
canalization. A large and somewhat effective collateral ve-
nous circulation through paravertebral veins and azygos
system was observed, and no interventional therapy was
attempted.
Left-sided common iliac vein stenosis was unmasked
after lysis in 3 patients. One underwent venous stenting (14
x 60 mm Wallstent) with technical success and a 12-week
follow-up patency. One refused to undergo angioplasty and
the other developed early rethrombosis (4 days after lysis)
before stenting.
Three other patients developed early rethrombosis, all
by 8 weeks after lytic therapy. No association was observed
between the episodes of rethrombosis and specific charac-
teristics, such as degree of lysis, side of the disease, asso-
ciate venous lesions, or others.
Late Results
Patients were divided in 2 groups according with the
final patency results as follows: individuals with initial lytic
failure or rethrombosis and individuals who presented ef-
fective thrombolysis and continued patency in terms of
clinical and duplex-scan late findings. Individual late re-
sults are summarized in Table 3. Apart from these differ-
ent outcomes, no other variable tested revealed any diver-
gence between the two groups. The mean clinical and
echographic follow-up periods were greater than 1 year and
are statistically similar between the groups (Table 4). In
Table 2 - Mean percentage thrombolysis vs acute clinical
improvement
Clinical Number of Average thrombus Range of thrombus
response cases removal (%) removal (%)
Absent 01 11 11
Poor 05 48.2 33-63
Significant 07 79 56-100
Complete 05 85 59-100
Spearman’s R = 0.723 (P < 0.01).
Table 3 - Late clinical and echographic results of
thrombolysis therapy
No. Result Severe Valve Chronic
Clinical Reflux Occlusions
Sequelae
1 Patency - - -
2 Patency - - -
3 Initial Failure + + -
4 Initial Failure + + +
5 Initial Failure + + +
6 Rethrombosis + + -
7 Patency + + -
8 Patency - - -
9 Patency - - -
10 Patency - - -
11 Rethrombosis + + +
12 Rethrombosis + + -
13 Patency - - -
14 Rethrombosis + + +
15 Patency + - -
16 Failure + + +
17 Patency - - -
18 Patency - - -
(+) present (-) absent
Table 4 - Period of clinical and duplex-scan follow-up (weeks)
Clinical Duplex-scan
General 85.2 ± 39.7 (12-131) 67.2 ± 32.7 (12-115)
Continued patency group 77.4 ± 41.3 (12-131) 59.8 ± 31.2 (12-99)
Initial failure / rethrombosis group 95.1 ± 37.8 (44-130) 76.4 ± 34.0 (44-115)
 P 0.46* 0.23*
Mean, standard deviation and minimum/ maximum values. *Mann-Whitney’s “U” test. Nonsignificant values.
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the 4 patients who presented rethrombosis, the initiation
of the follow-up period was established as beginning from
the new thrombotic episode.
The individuals with initial lytic failure or early
rethrombosis had a significantly higher incidence of severe
clinical signs and symptoms of post-thrombotic syndrome.
as well as venous reflux and chronic occlusions, compared
with those with long-time patency (Table 5). Also, patients
with preserved valve function displayed a lower incidence
of severe clinical sequelae, as did patients with complete
supragenicular recanalization (Table 6). Although no direct
fibrinolytic infusion was performed in the infragenicular
veins, a lower incidence of venous reflux in such segments
was also noted in patients of the long-time patency group.
None of the patients studied displayed clinical signs of
venous insufficiency of the lesser saphenous vein (when
used as access site) such as venous stasis or varicose
branches. Nevertheless, late control duplex-scans showed
evidence of 4 cases of reflux and 1 of occlusion of the
lesser saphenous vein. Significant correlations between
these lesser saphenous vein alterations and immediate or
late results were not observed. The small series made a
proper comparison of the different access techniques im-
possible.
DISCUSSION
Along with arterial occlusive disease20, post-thrombotic
syndrome is one of the vascular diseases that most fre-
quently lead to impaired quality-of-life.
Indication for lytic therapy for proximal DVT is still
fraught with controversy. Systemic fibrinolysis which was
tried in the past, with poor immediate results and an unac-
ceptable incidence of complications,21 was soon abandoned.
Current selective techniques of drug delivery have produced
better results but are restricted to very few medical centers,
most of them related to research activities. Possible rea-
sons for the resistance in accepting the method are lack of
appropriate material and human resources, poor experience
on the part of the vascular surgeons with US-guided vas-
cular access and fibrinolytic applications, and lack of solid
scientific conclusions about the cost-benefit ratio of throm-
bolysis. Economical aspects are another restrictive point,
even though the initial costs may be compensated by long-
term reduction of post-thrombotic syndrome complica-
tions.22
Patients with extensive DVT treated by anticoagulants
usually present fairly poor rates of spontaneous short-time
recanalization.23-25 Catheter-directed venous lysis enables
the changing of the natural history of venous thrombosis,
promoting early removal of the thrombus and re-establish-
ment of venous patency.
In this study, only 6.9% of the cases assessed were se-
lected for thrombolytic therapy. This figure is fairly close
to that reported by Markel et al26 and reflects the limited
character of lysis as therapy for DVT. Also, the strict ob-
servation of the inclusion and exclusion criteria resulted in
a small sample size that represents a limitation of the study.
In spite of such limitations, we were able to identify short-
and long-term results that, together with previous studies,
help in understanding the role and limitations of fibrinoly-
sis in DVT.
The main features of the dissection access of the lesser
saphenous vein include the following: technical accessibil-
Table 6 - Association between the degree of late clinical signs and symptoms of PTS and final duplex-scan pathologic
findings
Intensity of clinical signs and symptoms
Moderate / severe Absent / light P (Fisher test)
Supragenicular chronic occlusions 5/10 0/8 < 0.05
Infragenicular chronic occlusions 2/10 0/8 NS
Supragenicular valvular reflux 9/10 0/8 < 0.01
Infragenicular valvular reflux 7/10 0/8 < 0.01
PTS = post-thrombotic syndrome
Table 5 - Late results of patients showing venous patency or failure/rethrombosis
Continued patency group Initial failure / rethrombosis group P (Fisher test)
Supragenicular chronic occlusions 0/10 5/8 < 0.01
Infragenicular chronic occlusions 0/10 2/8 NS
Supragenicular valvular reflux 1/10 8/8 < 0.01
Infragenicular valvular reflux 1/10 6/8 < 0.05
Significant clinical symptoms 2/10 8/8 < 0.01
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ity; ease of accomplishment, elimination of the need for
complex infra-structure, as in the case of guided puncture
by echography; safety regarding puncture, because dissec-
tion is generally restricted to the superficial anatomic lay-
ers; and direct visualization of the lesser saphenous vein.
Moreover, unlike popliteal vein puncture, the risk of acci-
dental arterial puncture is eliminated.
In spite of the good results and the absence of major
complications, dissection of the lesser saphenous vein has
limitations, especially in its distal site. Primarily, the di-
ameter of the vein may be inadequate for passage of the
catheter, and anatomic variations or technical difficulties
may prevent the catheter from reaching the deep venous
system. The distal lesser saphenous vein may be unsuit-
able for introduction of large caliber devices, such as bal-
loons and stents for angioplasty, to treat venous stenosis
or spurs identified after lysis. This limitation is caused by
the reduced distal diameter of this vein and the distance
between the access site and the location of eventual lesions,
eg, iliac stenosis in May-Turner syndrome. The solution to
such a problem would be a second access through femoral
vein puncture. In the 2 cases of US-guided popliteal punc-
ture, there were no signs of hematoma or other complica-
tions. Iliac angioplasty and stenting was performed through
this access without difficulty. In the authors’ opinion, pos-
terior tibial vein dissection is an option that should usu-
ally be avoided.
In this study, improvement of symptoms during the
acute stage was significantly associated with success of the
thrombolysis, pointing to a direct relationship between the
volume of lysis and the degree of clinical improvement
shown. This evidence suggests the efficacy of lytic therapy
for alleviating exuberant symptoms related to extensive
DVT. The rate of early recanalization found in this study
is comparable to other series of lysis with other drugs or
with larger doses of rt-PA.7,10,27
In most studies of venous lysis of the lower limbs, the
selection of patients with acute DVT did not necessarily
exclude those suffering from previous venous insufficiency.
These studies focus their analysis on the immediate results
of thrombolytic treatment. However, the diversity of their
groups makes it difficult to identify the eventual benefits
of lysis on the clinical outcome of patients. In our study,
we excluded those subjects who displayed any evidence of
DVT or chronic venous insufficiency prior to the acute epi-
sode. Therefore, it was reasonable for us to conclude that
the presence of residual thrombosis and/or late valvular re-
flux in some patients was directly related to the studied
DVT episode.
In the present series, there were no clinically identifi-
able episodes of pulmonary embolism. The combined use
of thrombolytic infusion and lower doses of heparin that
was controlled and adjusted by partial thromboplastin time
seemed to create a state of systemic anticoagulation that
was sufficient for preventing extension of the thrombotic
process, as observed on the control phlebograms.
Bleeding at the catheter insertion site is a frequent com-
plication and to a certain extent predictable in arterial and
venous thrombolytic therapy.28 In this study, 4 of the 18
patients developed bleeding from the insertion site. For all
4 patients, local pressure bandages and elevation of the limb
were enough to stop or substantially reduce bleeding, with-
out requiring interruption of therapy. This observation is a
point in favor of the safety of this lesser saphenous vein
dissection approach combined with the use of low doses
of rt-PA.
Only 1 patient exhibited spontaneous bleeding, charac-
terized by gross hematuria, which is comparable to reports
of many other series. Although 1 patient developed bleed-
ing with hematoma in the upper limb, this was not a spon-
taneous event, but was more of a iatrogenic outcome due
to many attempts to obtain a blood sample in a deep layer.
This complication can be prevented by simple standardi-
zation of assay procedures such as specific orientation to
avoid deep vein or arterial punctures and preparation of
venous access for blood collection before starting fibrinoly-
sis. No patient in the study presented systemic bleeding
with hemodynamic instability or requiring transfusion, nor
were there episodes of intracranial hemorrhage or deaths
in the acute stage.
The mean clinical follow-up time was 85 weeks. Al-
though this time is insufficient to observe late changes re-
lated to post-thrombotic syndrome such as cutaneous
hyperpigmentation and phlebopathic ulcers, we believe it
is adequate to assess early signs of venous insufficiency,
such as discomfort, pain, and persistent edema.
Follow-up time was sufficient to obtain conclusive re-
sults regarding venous reflux by duplex scanning. Deve-
lopment of reflux after DVT is usually an early manifesta-
tion. However, this can be a temporary6 alteration caused
by the presence of thrombi next to the valve cusps. Once
the thrombi are removed by the endogenous lysis, the val-
vular segments could eventually become competent again.
Average echographic follow-up time in this series was
about 67 weeks, time enough for 13 patients to attain total
recanalization and the remaining 5 to reveal patent venous
segments capable of echographic evaluation for the pres-
ence of reflux. These facts underscore the validity of the
results and minimize the risk of an incorrect evaluation,
wich might follow the interpretion of fortuitous findings
of transitory reflux as definitive consequences of the pro-
cedure.
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Preservation of patency obtained with rt-PA depends on
various factors, some of which are difficult to determine
and control, such as the presence of thrombophilias. Pa-
tient adherence to the anticoagulation program is also a
decisive factor. In this investigation, lack of patient com-
mitment to warfarin therapy and control was responsible
for at least 2 cases of rethrombosis.
Although this was a prospective investigation, there was
never an attempt to create an initial control group with con-
ventional anticoagulation therapy. The main reason for this
decision was the restrictive criteria of patient selection,
which resulted in a small number of cases. A correct con-
trol group would have to be formed from a randomization
of patients with the same clinical characteristics, resulting
in the need of doubling the number of cases, making the
study not feasible for a single-center investigation. Alter-
native nonrandomized control groups formed by patients
with exclusion criteria would probably bring differences in
the incidence and distribution of factors such as age, ve-
nous insufficiency, and other morbidities that would result
in biases. For these reasons, this study and most of the simi-
lar investigations consist of a series of cases. Unintention-
ally, concerning the late results, the 8 patients with acute
thrombolytic failure or early rethrombosis acted as a con-
trol group in comparison with the long-term effective
thrombolysis group.
The difference in clinical and echographic outcome be-
tween the patients with long-term patency and those with
initial lytic failure or early rethrombosis was clear, despite
the small series. The outcome of the former was charac-
terized by a lower incidence of clinical sequelae and ve-
nous reflux and complete recanalization of residual
thrombi. On the other hand, only 3 of the 8 patients of the
failure/rethrombosis group displayed complete recanaliza-
tion, with the common presence of valvular insufficiency
and late severe clinical symptoms. Even with partial reca-
nalization, the patent segments of the patients in this group
showed significant reflux.
Although infragenicular veins are not directly exposed
to thrombolysis, data showed that patients with effective
therapy had better results regarding valvular preservation
than the others. One possibility is that massive
supragenicular thrombotic removal may favor early reca-
nalization of tibial and sural veins, with better chances of
valve preservation.
The possibility that early venous thrombolysis could
promote preservation of venous function has always been
considered. However, only recently have studies been pub-
lished mentioning midterm follow-up of subjects treated by
fibrinolysis. AbuRhama et al29 studied patients with DVT
divided into groups treated by lysis or conventional anti-
coagulation; they perceived greater persistence of clinical
symptoms and valve reflux in the latter group. Elsharawyy
and Elzayat30 observed patients treated by anticoagulation
or lysis for 6 months after initial therapy and noted a lower
incidence of reflux in the thrombolysis group. Neverthe-
less, the reports mentioned differ from this study in choice
of lytic agent and dosage of rt-PA.
In most of the series reported,7,10,14,27 a significant per-
centage of patients underwent complementary procedures,
notably angioplasties or venous stenting. But, although
these procedures are associated to good technical success
and patency over the midterm,31-33 there are no conclusive
data regarding late outcome. In our series, 3 patients had
venous stenosis with indication for angioplasty. Other re-
sidual occlusions were observed in sites not usually related
to venous stenosis that later presented with spontaneous re-
canalization without clinical or echographic evidence of
residual stenosis. It appears that despite segmental occlu-
sions observed in some patients, a significant reduction of
thrombotic volume may result in facilitation of the rapid
removal of residual thrombi by the endogenous fibrinolytic
system. In our series, 50% to 100% thrombus removal was
achieved in an average of 42 hours, while Meissner et al34
reported a mean period of 3.4 months for endogenous re-
moval of 50% of thrombi in lower limb DVT.
Less than half (8 of 18) of the treated patients showed
good long-term clinical results. Although this observation
may at first seem to discourage lytic therapy, further con-
sideration reveals that it represents a huge improvement
compared to classical anticoagulation therapy for extensive
DVT, considering that benign evolution in such cases is
rare.3-5
Comerota et al35 verified that subjects with DVT un-
dergoing successful thrombolysis had a better life quality
and lower incidence of post-thrombotic syndrome. symp-
toms than individuals treated only with anticoagulants. The
present study compiled similar evidence, establishing a re-
lationship between the effectiveness of the thrombolytic
method and the favorable late clinical results, resulting in
preservation of life quality in patients with successful
therapy.
In conclusion, catheter-directed thrombolysis with low
doses of rt-PA for treatment of acute DVT displayed good
immediate success and absence of severe complications. In
individuals in whom lysis was effective and the patency
obtained was preserved, the incidence of late clinical and
echographic alterations was notably minor.
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RESUMO
Casella IB, Presti C, Aun R, Benabou JE, Puech-Leão P.
Resultados de longo prazo do tratamento fibrinolítico da
trombose venosa iliacofemoral por infusão seletiva do
ativador de plasminogênio tissular recombinante em bai-
xas doses. Clinics. 2007;62(1):31-40.
OBJETIVOS: Avaliar a eficácia da infusão seletiva por
cateter do ativador de plasminogênio tecidual recombinante
em baixas doses no tratamento da trombose venosa
iliacofemoral e na prevenção da síndrome pós-trombótica.
MÉTODO: Dezoito pacientes (de 260 avaliados) portado-
res de trombose venosa profunda iliacofemoral sem evidên-
cia prévia de insuficiência venosa foram selecionados para
terapia fibrinolítica e submetidos a infusão seletiva por ca-
teter do ativador de plasminogênio tecidual recombinante
na dose de 1mg/dl nos segmentos venosos trombóticos.
RESULTADOS: Quatorze pacientes apresentaram
fibrinólise efetiva; observamos correlação entre o grau de
melhora clínica observado e a redução percentual do vo-
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